Combination of sorafenib and cytokine-induced killer cells in metastatic renal cell carcinoma: a potential regimen.

about

Combination of sorafenib and cytokine-induced killer cells in metastatic renal cell carcinoma: a potential regimen.

Item

http://www.wikidata.org/entity/Q52856745

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Combination of sorafenib and c ...... arcinoma: a potential regimen.

@en

Combination of sorafenib and c ...... arcinoma: a potential regimen.

@nl

type

Item

label

Combination of sorafenib and c ...... arcinoma: a potential regimen.

@en

Combination of sorafenib and c ...... arcinoma: a potential regimen.

@nl

prefLabel

Combination of sorafenib and c ...... arcinoma: a potential regimen.

@en

Combination of sorafenib and c ...... arcinoma: a potential regimen.

@nl

P1476

Combination of sorafenib and c ...... arcinoma: a potential regimen.

@en

P2093

Hongwei Lin

http://www.w3.org/2001/XMLSchema#string

Lingdi Zhao

http://www.w3.org/2001/XMLSchema#string

Quanli Gao

http://www.w3.org/2001/XMLSchema#string

Yonghao Yang

http://www.w3.org/2001/XMLSchema#string

Yongping Song

http://www.w3.org/2001/XMLSchema#string

P2860

Serial low doses of sorafenib enhance therapeutic efficacy of adoptive T cell therapy in a murine model by improving tumor microenvironment

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

Cancer treatment and survivorship statistics, 2014

Immunosuppressive strategies that are mediated by tumor cells

Redirecting the immune response: role of adoptive T cell therapy.

Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines.

BAY 43-9006 inhibition of oncogenic RET mutants.

A systematic review of the efficacy and safety experience reported for sorafenib in advanced renal cell carcinoma (RCC) in the post-approval setting.

The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors

TLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progression

P304

629-635

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/IMT-2016-0133

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28653574

http://www.w3.org/2001/XMLSchema#string